Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
- 15 February 2024 - 1 mins read
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment
Related Press Releases

07 May 2025
7 mins read
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary...

06 May 2025
5 mins read
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

24 April 2025
7 mins read
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

16 April 2025
6 mins read
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

08 April 2025
4 mins read
Ipsen publishes its 2024 Universal Registration Document

19 March 2025
7 mins read
Ipsen announces issuance of €500 million inaugural Rated Public Bond

12 March 2025
5 mins read
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

13 February 2025
6 mins read
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

03 December 2024
6 mins read
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

18 November 2024
12 mins read